Overview

Immune Repertoire Sequencing Market Introduction

Immune repertoire sequencing market is forecasted to value over US$ 175 Million by 2027 end and register a CAGR of over 7.5% from 2020 to 2027.
Human adaptive immune system protection is brought to the surface of B-cell receptor (BCR) and T-cell receptor(TCR) by receptors. Advancements in next-generation sequencing (NGS) have allowed the birth of new technology in the form of immune repertoire sequencing. It delves in determining the region of the receptors. It helps in delivering information regarding the antigen-specific present within lymphocytes.

Increasing support from government regarding pharmacogenomics-based drug recovery has boosted the growth of the market. The rapid increase in multiple therapeutic areas like pain management, infectious diseases, cardiology, and oncology is stimulating the size of the market as well. In addition, various organizations aiming to look for solutions regarding biomarkers in the immune system has also been driving the growth of the market. Manufacturers merging is also fueling the growth of the market. For example, Ambry Genetics and ArcherDX Inc. merged together to deliver immune repertoire sequencing services to customers of the biopharmaceutical.

The immune repertoire sequencing market is segmented by product, by application, and by the end user. By product, the market is bifurcated into assay kits and software & services. The assay kits are further divided into TCR Kits and BCR Kits. Assay kit is expected to hold a major share of the market in the forecast period.

TCR plays an essential role in the human adaptive immune system. It recalls, destructs and recognizes the pathogenic agents. Multiple companies are looking for merging in order to develop repertoire sequencing kits for immunotherapy response of a specific kind. For example, MIODx and DiaCarta collaborated together to develop MIODX's ClonoMapto predict the response of the patient to immunotherapy.

On the basis of software & services, the market is bifurcated into analytical software, sequencing services, and data analysis services. 
The end users of the market are infectious diseases, vaccine development, cancer immunotherapy, autoimmune disease, and transplant rejection & tolerance. Rising infectious diseases, advancement in vaccine development and research regarding cancer immunotherapy is expected to drive the growth of the market. 

In terms of region, North America is expected to hold a vast share of the market. Presence of a vast number of prominent players alongside growing attention towards novel technology for immune repertoire sequencing remains the key factor behind the growth of the market in the region. 10x Genomics Inc, a US-based company included 5'Unbiased Enrichment Kit to immune repertoire sequencing.

Europe is expected to achieve the highest growth in the forecast period. The increased funding by the government alongside rising healthcare expenditure is expected to expand the size of the market in the region. Asia-Pacific region is also predicted to show immense growth of the market in the coming years. Rising health infrastructure in developing countries like China and Japan is also boosting the growth of the market in the region. 

Prominent players of the market are:

ABVITRO (NOW JUNO THERAPEUTICS), ADAPTIVE BIOTECHNOLOGIES, AGILENT TECHNOLOGIES, ARCHERDX, INC., BGI, ILLUMINA, INC., IREPERTOIRE, INC., OXFORD NANOPORE TECHNOLOGIES, LTD, PACIFIC BIOSCIENCES, Qiagen N.V., Takara Bio Inc., CD Genomics, Roche Holding AG  and Thermo Fisher Scientific

Immune Repertoire Sequencing Market Segmentation: 

By Product

• Instrument
• NGS
• PCR
• Assay, Kits and Reagent
• TCR Kits
• Human TCR Kits
• Mouse TCR Kits
• BCR Kits
• Human BCR Kits
• Mouse BCR Kits
• Analytical Software
• TCR Analysis Solutions
• BCR Analysis Solutions
• TCR & BCR Analysis Solutions
• Services
• Pre-Sequencing Services
• Sequencing Services
• Data Analysis Services

By Application

• Biomarker Discovery
• Autoimmune Diseases
• Cancer Immunotherapy
• Infectious Disease Research
• Asthma and Allergy Research
• Vaccine Development
• Immunodeficiency Identification
• Others (If Any)

By End User

• Diagnostic Labs
• Pharmaceutical and Biotech Companies
• Research Institutes
• Others (If Any)

By Region

• North America
• Europe
• Asia-Pacific
• Rest of the world

Competitive Landscape:  
•    Tier 1 players- established companies in the market with a major market share  
•    Tier 2 players 
•    Emerging players which are growing rapidly 
•    New Entrants   

FutureWise Takeaways: 
•    Growth prospects  
•    SWOT analysis 
•    Key trends 
•    Key data points affecting market growth  

Objectives of the Study: 
•    To provide with an exhaustive analysis on the immune repertoire sequencing market based on the products, application, end users and region 
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) 
•    To evaluate and forecast micro-markets and the overall market  
•    To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East
•    To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions 
•    Profiling of companies to evaluate their market shares, strategies, financials and core competencies  

Flexible Delivery Model

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
          1.1 Objectives of the Study 
          1.2 Market Definition 
          1.3 Market Scope 
               1.3.1 Years Considered for the Study
               1.3.2 Market Covered
          1.4 Currency 
          1.5 Limitations 
          1.6 Stakeholders 
 2.  Research Methodology 
      2.1 Research Data 
         2.1.1 Secondary Data
                 2.1.1.1 Key Data from Secondary Sources
         2.1.2 Primary Data
                 2.1.2.1 Key Data from Primary Sources
      2.2 Market Size Estimation 
      2.3 Market Breakdown and Data Triangulation 
      2.4 Assumptions for the Study  
3. Executive Summary
        3.1 Market Outlook
        3.2 Segment Outlook
        3.3 Competitive Insights
4. Global Market Variables, Trends & Scope
       4.1. Market Lineage Outlook
       4.2. Penetration and Growth Prospect Mapping
       4.3. Application Value Chain Analysis
       4.4. Cost Analysis Breakdown
       4.5. Disease Indication Overview
       4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances
5. Global Market Overview
     5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                            5.1.1.1. Increasing focus of Immune Repertoire Sequencing Companies on Brand Protection
                            5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                            5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Application Challenges
                            5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Market Analysis Tools
         6.1. Application Analysis - Porter’s
               6.1.1. Supplier Power
               6.1.2. Buyer Power
               6.1.3. Substitution Threat
               6.1.4. Threat from New Entrants
               6.1.5. Competitive Rivalry
         6.2. Pestel Analysis
               6.2.1. Political Landscape
               6.2.2. Environmental Landscape
               6.2.3. Social Landscape
               6.2.4. Disease Indication Landscape
               6.2.5. Legal Landscape
         6.3. Major Deals And Strategic Alliances Analysis
                6.3.1. Joint Ventures
                6.3.2. Mergers and Acquisitions
                6.3.3. Licensing and Partnership
                6.3.4. Disease Indication Collaborations
                6.3.5. Strategic Divestments
         6.4. Market Entry Strategies
         6.5. Case Studies
7. Global Immune Repertoire Sequencing Market, By Product Historical Analysis and Forecast 2020-2027 (USD Million)
     7.1. Instrument 
           7.1.1. NGS
           7.1.2. PCR
     7.2. Assay, Kits and Reagent 
           7.2.1. TCR Kits
                    7.2.1.1. Human TCR Kits
                    7.2.1.2. Mouse TCR Kits
           7.2.2. BCR Kits
                    7.2.2.1. Human BCR Kits
                    7.2.2.2. Mouse BCR Kits
     7.3. Analytical Software
           7.3.1. TCR Analysis Solutions
           7.3.2. BCR Analysis Solutions
           7.3.3. TCR & BCR Analysis Solutions
     7.4. Services
           7.4.1. Pre-Sequencing Services
           7.4.2. Sequencing Services
           7.4.3. Data Analysis Services
8. Global Immune Repertoire Sequencing Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)
     8.1. Biomarker Discovery
     8.2. Autoimmune Diseases
     8.3. Cancer Immunotherapy
     8.4. Infectious Disease Research
     8.5. Asthma and Allergy Research
     8.6. Vaccine Development
     8.7. Immunodeficiency Identification
     8.8. Others (If Any)
9. Global Immune Repertoire Sequencing Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million)
     9.1. Diagnostic Labs
     9.2. Pharmaceutical and Biotech Companies
     9.3. Research Institutes
     9.4. Others (If Any)
10. North America Immune Repertoire Sequencing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
     10.1. Introduction
     10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
            10.2.1. U.S.A
            10.2.2. Canada
            10.2.3. Mexico
     10.3. Market Size (USD Million) Forecast for North America 2020-2027              
11. Latin America Immune Repertoire Sequencing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
     11.1. Introduction
     11.2. Regional Market Trends
     11.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019
            11.3.1. Brazil
            11.3.2. Venezuela
            11.3.3. Argentina
            11.3.4. Rest of Latin America
     11.4. Market Size (USD Million) Forecast for Latin America 2020-2027  
12. Europe Immune Repertoire Sequencing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
     12.1. Introduction
     12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
            12.2.1. Germany
            12.2.2. U.K
            12.2.3. France
            12.2.4. Italy
            12.2.5. Spain
            12.2.6. Russia
            12.2.7. Poland
            12.2.8. Switzerland
            12.2.9. Rest of Western Europe
       12.3. Market Size (USD Million) Forecast for Europe 2020-2027
13. Asia Pacific Immune Repertoire Sequencing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        13.1. Introduction
        13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
             13.2.1. Japan
             13.2.2. China
             13.2.3. Singapore
             13.2.4. India
             13.2.5. Australia and New Zealand
             13.2.6. ASEAN
             13.2.7. South Korea
             13.2.8. Rest of Asia Pacific
        13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
14. Middle East and Africa Immune Repertoire Sequencing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        14.1. Introduction
        14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
             14.2.1. Saudi Arabia
             14.2.2. UAE
             14.2.3. South Africa
             14.2.4. Egypt
        14.3. Market Size (USD Million) Forecast for MEA 2020-2027
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
         15.1. ABVITRO (NOW JUNO THERAPEUTICS)
                15.1.1. Company Overview
                15.1.2. Product Portfolio
                15.1.3. SWOT Analysis
                15.1.4. Financial Overview
                15.1.5. Strategic Overview
         15.2. ADAPTIVE BIOTECHNOLOGIES
                15.2.1. Company Overview
                15.2.2. Product Portfolio
                15.2.3. SWOT Analysis
                15.2.4. Financial Overview
                15.2.5. Strategic Overview
         15.3. AGILENT TECHNOLOGIES
                15.3.1. Company Overview
                15.3.2. Product Portfolio
                15.3.3. SWOT Analysis
                15.3.4. Financial Overview
                15.3.5. Strategic Overview
            15.4. ARCHERDX, INC.
                15.4.1. Company Overview
                15.4.2. Product Portfolio
                15.4.3. SWOT Analysis
                15.4.4. Financial Overview
                15.4.5. Strategic Overview
            15.5 BGI
                15.5.1. Company Overview
                15.5.2. Product Portfolio
                15.5.3. SWOT Analysis
                15.5.4. Financial Overview
                15.5.5. Strategic Overview
            15.6 ILLUMINA, INC.
                15.6.1. Company Overview
                15.6.2. Product Portfolio
                15.6.3. SWOT Analysis
                15.6.4. Financial Overview
                15.6.5. Strategic Overview
      15.7. IREPERTOIRE, INC.
                15.7.1. Company Overview
                15.7.2. Product Portfolio
                15.7.3. SWOT Analysis
                15.7.4. Financial Overview
                15.7.5. Strategic Overview
         15.8. OXFORD NANOPORE TECHNOLOGIES, LTD
                15.8.1. Company Overview
                15.8.2. Product Portfolio
                15.8.3. SWOT Analysis
                15.8.4. Financial Overview
                15.8.5. Strategic Overview
         15.9. PACIFIC BIOSCIENCES
                15.9.1. Company Overview
                15.9.2. Product Portfolio
                15.9.3. SWOT Analysis
                15.9.4. Financial Overview
                15.9.5. Strategic Overview
           15.10. Qiagen N.V.
                15.10.1. Company Overview
                15.10.2. Product Portfolio
                15.10.3. SWOT Analysis
                15.10.4. Financial Overview
                15.10.5. Strategic Overview
           15.11 Takara Bio Inc.
                15.11.1. Company Overview
                15.11.2. Product Portfolio
                15.11.3. SWOT Analysis
                15.11.4. Financial Overview
                15.11.5. Strategic Overview
            15.12 Thermo Fisher Scientific
                15.12.1. Company Overview
                15.12.2. Product Portfolio
                15.12.3. SWOT Analysis
                15.12.4. Financial Overview
                15.12.5. Strategic Overview
             15.13. CD Genomics
                15.13.1. Company Overview
                15.13.2. Product Portfolio
                15.13.3. SWOT Analysis
                15.13.4. Financial Overview
                15.13.5. Strategic Overview
           15.14. Roche Holding AG
                15.14.1. Company Overview
                15.14.2. Product Portfolio
                15.14.3. SWOT Analysis
                15.14.4. Financial Overview
                15.14.5. Strategic Overview
16. FutureWise SME Key Takeaway Points for Client

Tables

Figures